- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00748527
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether carboplatin is more effective with or without decitabine in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
PURPOSE: This randomized phase II trial is studying carboplatin and decitabine to see how well they work compared with carboplatin alone in treating patients with progressive, advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
OBJECTIVES:
Primary
- To compare the response rate in patients with progressive, advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer who have methylated hMLH1 DNA in plasma treated with carboplatin with vs without decitabine.
Secondary
- To compare the response rate in all patients (regardless of methylation status) treated with these regimens.
- To compare the progression-free survival and overall survival of patients treated with these regimens.
- To compare the safety and tolerability of these regimens.
- To determine the feasibility of combining decitabine with carboplatin.
- To determine the incidence of hypersensitivity reactions to carboplatin.
- To study the relationship between peak plasma levels of decitabine and global or CpG island specific methylation.
- To study the relationship between global and gene specific methylation in peripheral blood mononuclear cells and response.
Tertiary
- To correlate the methylation status of genes associated with drug resistance detected in plasma DNA with response.
- To determine the sensitivity and specificity of methylation of genes associated with drug resistance detected in plasma DNA as a predictor of methylation status in tumor cells isolated from ascites or tumor biopsy.
- To study methylation and expression of genes in tumor cells isolated from ascites or tumor biopsy before and after treatment with decitabine and/or carboplatin.
- To investigate any correlation between methylation and expression of genes in surrogate tissues, body fluids, or tumor cells and response or progression-free survival.
- To examine markers of cell death in plasma.
- To compare the methylation in tumor taken at the time of presentation vs at the time of treatment.
OUTLINE: This is a multicenter study. Patients are stratified according to prior first-line treatment (platinum alone vs platinum and taxane vs platinum and other combination), WHO performance status (0 vs 1 vs 2), measurable disease criteria (RECIST criteria vs CA-125 criteria vs both), participating center, and the number of prior platinum-based regimens (1 vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive carboplatin IV over 30-60 minutes on day 1.
- Arm II: Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
In both arms, treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection periodically for pharmacodynamic studies. Samples are assessed for methylation of hMLH1 by methylation-specific PCR; global DNA methylation by high performance liquid chromatography (HPLC) ; methylation of the MAGE-1A gene promoter by methylation-specific PCR or bisulfite pyrosequencing; and markers of apoptosis by ELISA. Pharmacokinetic studies of decitabine are also performed using blood samples from patients randomized to arm II. Ascitic fluid and/or tumor tissue samples may also be collected for pharmacodynamic studies.
After completion of study treatment, patients are followed at 28 days and then every 2 months thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Tanulmány típusa
Beiratkozás (Várható)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
England
-
Leeds, England, Egyesült Királyság, LS9 7TF
- Leeds Cancer Centre at St. James's University Hospital
-
Leicester, England, Egyesült Királyság, LE1 5WW
- Leicester Royal Infirmary
-
London, England, Egyesült Királyság, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Egyesült Királyság, SW3 6JJ
- Royal Marsden - London
-
London, England, Egyesült Királyság, W12 OHS
- Hammersmith Hospital
-
Northwood, England, Egyesült Királyság, HA6 2RN
- Mount Vernon Cancer Centre at Mount Vernon Hospital
-
Sutton, England, Egyesült Királyság, SM2 5PT
- Royal Marsden - Surrey
-
Weston-super-Mare, England, Egyesült Királyság, BS23 4TQ
- Weston General Hospital
-
-
Northern Ireland
-
Belfast, Northern Ireland, Egyesült Királyság, BT8 8JR
- Belfast City Hospital Trust Incorporating Belvoir Park Hospital
-
-
Scotland
-
Edinburgh, Scotland, Egyesült Királyság, EH4 2XU
- Edinburgh Cancer Centre at Western General Hospital
-
Glasgow, Scotland, Egyesült Királyság, G12 0YN
- Beatson West of Scotland Cancer Centre
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
DISEASE CHARACTERISTICS:
Histologically or cytologically proven ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer
- Progressive disease as defined by RECIST criteria and/or CA-125 criteria
- Advanced disease
Previously treated with 1-2 prior platinum-containing regimen(s)
- Prior hormonal therapy does not count towards the prior treatment
- Responded to the most recent prior platinum-containing regimen(s) OR no evidence of progression during platinum-containing therapy as documented by RECIST criteria or CA-125 criteria (for patients with no macroscopic residual disease after surgery who are not evaluable by CA-125)
Disease relapse 6-12 months after completion of the most recent platinum-containing therapy
- Patients who received two prior lines of treatment must have had ≥ 6 months between their first and second lines of treatment
- Patients with disease progression, as defined by CA-125 criteria alone, within 6 months after completion of their last treatment are eligible provided study treatment commences > 6 months after the last prior treatment
- Patients with disease progression, as defined by GCIG guidelines, within 12 months after completion of their last treatment are eligible provided study treatment commences ≤ 14 months after the last prior treatment
Measurable disease by RECIST criteria and/or CA-125 criteria
- Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques (physical examination, CT scan, x-ray, or MRI) or as ≥ 10 mm by spiral CT scan
- Patients with evaluable disease by CA-125 criteria are eligible provided CA-125 is ≥ 2 times upper limit of normal (ULN) within 2 weeks prior to initiating study treatment
- Disease is not considered measurable if patient received prior mouse antibodies or if there has been medical and/or surgical interference with the peritoneum or pleura (e.g., paracentesis) within the past 28 days
Ascites requiring therapeutic drainage allowed only if there is measurable disease by RECIST criteria
- Ascites that do not require therapeutic drainage allowed even if disease is evaluable by CA-125 criteria alone
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Hemoglobin ≥ 10.0 g/dL
- WBC ≥ 3.0 x 10^9/L
- Neutrophil count ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Bilirubin ≤ 30 μmol/L
- ALT and/or AST ≤ 2.5 times ULN (≤ 5 times ULN if due to tumor involvement of liver)
- EDTA/DTPA clearance ≥ 50 mL/min (uncorrected value)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception for 4 weeks prior to, during, and for 6 months after completion of study treatment
- No known hepatitis B, hepatitis C, or HIV positivity
- No non-malignant systemic disease, including active uncontrolled infection, that would make the patient a high medical risk
No other current malignancies, except adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin
- Patients who have undergone potentially curative therapy for a prior malignancy are eligible provided there is no evidence of disease for ≥ 5 years and the patient is deemed to be at low risk for recurrence
No intolerance to carboplatin (with a dose of ≥ AUC 5), as defined by any of the following:
- Neutropenia or thrombocytopenia causing dose delay of > 4 days on more than 2 occasions
- Grade III or IV hypersensitivity reaction (not controlled by a desensitization regimen)
- Hospitalization for confirmed febrile neutropenia (fever ≥ 38°C)
- Requirement for platelet transfusion
- No other condition that, in the investigator's opinion, would not make the patient a good candidate for this study
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy (alopecia, grade 1 neuropathy, and certain grade 1 toxicities allowed)
- More than 28 days since prior maintenance therapy (e.g., erlotinib or bevacizumab)
- More than 4 weeks since prior radiotherapy, endocrine therapy, immunotherapy, chemotherapy, biological therapy, or investigational agents
- More than 4 weeks since prior major thoracic and/or abdominal surgery and recovered
- No other concurrent anti-cancer therapy, including radiotherapy or investigational drugs
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Aktív összehasonlító: Arm I
Patients receive carboplatin IV over 30-60 minutes on day 1.
|
Adott IV
|
Kísérleti: Arm II
Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
|
Adott IV
Adott IV
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
---|
Response rate (partial response [PR] or complete response [CR]) in patients with methylated hMLH1 DNA in plasma as measured by RECIST criteria or CA-125 criteria
|
Másodlagos eredményintézkedések
Eredménymérő |
---|
Response rate (PR or CR) in all patients (regardless of methylation status) as measured by RECIST criteria or CA-125 criteria
|
Progressziómentes túlélés és általános túlélés
|
Adverse events as measured by NCI CTCAE v3.0
|
Total dose and dose intensity of carboplatin and decitabine
|
Incidence of grade 3-4 hypersensitivity reactions
|
Correlation between peak plasma levels of decitabine and global and CpG island specific DNA methylation in peripheral blood mononuclear cells
|
Correlation between response (PR or CR) and global and CpG island specific DNA methylation in peripheral blood mononuclear cells
|
Correlation between response (PR or CR) and CpG island specific DNA methylation in plasma DNA
|
CpG island specific DNA methylation in plasma and tumor DNA
|
CpG island specific DNA methylation in tumor DNA and expression of genes as measured by RNA or protein assays
|
Correlation between response (PR, CR, or stable disease) and CpG island specific DNA methylation in tumor DNA and expression of genes by RNA or protein assays
|
Immunoassays of proteins in plasma
|
CpG island specific DNA methylation in tumor DNA
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi szék: Stanley B. Kaye, MD, FRCP, Royal Marsden NHS Foundation Trust
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Neoplazmák szövettani típus szerint
- Neoplazmák
- Urogenitális neoplazmák
- Neoplazmák webhelyenként
- Karcinóma
- Neoplazmák, mirigyes és epiteliális
- Nemi szervek daganatai, nők
- Endokrin rendszer betegségei
- Petefészek betegségek
- Adnexális betegségek
- Gonád rendellenességek
- Endokrin mirigy neoplazmák
- Petevezeték betegségei
- Petefészek neoplazmák
- Petevezeték neoplazmák
- Karcinóma, petefészek epitélium
- A farmakológiai hatás molekuláris mechanizmusai
- Enzim gátlók
- Antimetabolitok, daganatellenes
- Antimetabolitok
- Antineoplasztikus szerek
- Carboplatin
- Decitabin
Egyéb vizsgálati azonosító számok
- CRUK-PH2/051
- CDR0000613805 (Registry Identifier: PDQ (Physician Data Query))
- EUDRACT-2006-002324-41
- MGI-CRUK-PH2/051
- CTA-21106/0219/001
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Petefészekrák
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Még nincs toborzásAnatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Korai stádiumú emlőkarcinóma | Anatómiai Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Fred Hutchinson Cancer CenterMég nincs toborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
University of Southern CaliforniaNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Invazív emlőkarcinómaEgyesült Államok
-
National Cancer Institute (NCI)Aktív, nem toborzóRosszindulatú szilárd daganat | Anatómiai Stage III Breast Cancer AJCC v8 | Anatómiai Stage IV Breast Cancer AJCC v8 | Invazív emlőkarcinóma | Mell adenokarcinómaEgyesült Államok
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institute on Aging (NIA)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Mayo ClinicNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
City of Hope Medical CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | HER2-negatív emlőkarcinómaEgyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveVékonybél adenokarcinóma | III. stádiumú vékonybél-adenokarcinóma AJCC v8 | IIIA stádiumú vékonybél adenokarcinóma AJCC v8 | IIIB stádiumú vékonybél adenokarcinóma AJCC v8 | IV. stádiumú vékonybél adenokarcinóma AJCC v8 | Vater adenokarcinóma ampulla | Stage III Ampull of Vater Cancer AJCC v8 | Stage... és egyéb feltételekEgyesült Államok
Klinikai vizsgálatok a karboplatin
-
Instituto Nacional de Cancerologia de MexicoToborzásTüdőrák | Sarcopenia | ToxicitásMexikó
-
James ElderBefejezveFelnőttkori anaplasztikus asztrocitóma | Felnőttkori anaplasztikus oligodendroglioma | Ismétlődő felnőttkori agydaganatEgyesült Államok
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)BefejezveIsmétlődő nem kissejtes tüdőrák | IV. stádiumú nem kissejtes tüdőrákEgyesült Államok
-
Northwestern UniversityEisai Inc.IsmeretlenFérfi mellrák | II. stádiumú mellrák | IIIA stádiumú mellrák | IIIB stádiumú mellrák | Háromszoros negatív mellrák | IA stádiumú mellrák | IB stádiumú mellrák | IIIC stádiumú mellrák | Ösztrogénreceptor-negatív emlőrák | Progeszteron-receptor-negatív emlőrák | HER2-negatív emlőrákEgyesült Államok
-
National Cancer Institute (NCI)Gynecologic Oncology GroupBefejezvePetevezető rák | Ovarian Clear Cell Cystadenocarcinoma | Petefészek endometrioid adenokarcinóma | Petefészek savós cisztadenokarcinóma | Elsődleges peritoneális üregrák | Brenner-daganat | Ismétlődő petefészek-hámrák | Petefészek mucinosus cisztadenokarcinóma | Petefészek vegyes epiteliális karcinóma | Differenciálatlan...Egyesült Államok
-
Shanghai General Hospital, Shanghai Jiao Tong University...IsmeretlenKasztráció-rezisztens prosztatarák
-
Heath SkinnerToborzásOropharynx rákEgyesült Államok
-
Jonsson Comprehensive Cancer CenterTetraLogic Pharmaceuticals; California Institute for Regenerative Medicine (CIRM); Alpha Stem Cell Clinic (ASCC)VisszavontIsmétlődő petevezető karcinóma | Ismétlődő petefészek-karcinóma | Ismétlődő primer peritoneális karcinóma | Elsődleges peritoneális magas fokú savós adenokarcinóma | Magas fokú petefészek savós adenokarcinóma | Magas fokú petevezeték savós adenokarcinómaEgyesült Államok
-
National Cancer Institute (NCI)BefejezveMeghatározatlan felnőttkori szilárd daganat, protokoll specifikusEgyesült Államok
-
LungenClinic GrosshansdorfIsmeretlenNem kissejtes tüdőrákNémetország